NO943198L - Antisensoligonukleotidinhibering av papillomavirus - Google Patents
Antisensoligonukleotidinhibering av papillomavirusInfo
- Publication number
- NO943198L NO943198L NO943198A NO943198A NO943198L NO 943198 L NO943198 L NO 943198L NO 943198 A NO943198 A NO 943198A NO 943198 A NO943198 A NO 943198A NO 943198 L NO943198 L NO 943198L
- Authority
- NO
- Norway
- Prior art keywords
- papillomavirus
- oligonucleotides
- antisense oligonucleotide
- messenger rna
- oligonucleotide inhibition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/708—Specific hybridization probes for papilloma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Ollgonukleotider som har evne til antisensinteraksjon med messenger RNA til papillomavirus er beskrevet. Disse oligonukleotidene eller oligonukleotidanalogene kan bli anvendt for diagnostikk og som terapeutiske midler samt for forskning. Oligonukleotidene er hybrldlserbare med valgte messenger RNA fra et humant papilomavirus. Oligonukleotidet kan inhibere funksjon til RNA og er derfor nyttig for terapi for infeksjoner med slike papillomavirus. Deler av paplllomaviruset blir målsøkt for antisensangrep. Nukleotidene hybridi- serer med E2, E6 og E7 messenger RNA.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/860,925 US5457189A (en) | 1989-12-04 | 1992-03-31 | Antisense oligonucleotide inhibition of papillomavirus |
PCT/US1993/003075 WO1993020095A1 (en) | 1992-03-31 | 1993-03-31 | Antisense oligonucleotide inhibition of papillomavirus |
Publications (2)
Publication Number | Publication Date |
---|---|
NO943198L true NO943198L (no) | 1994-08-29 |
NO943198D0 NO943198D0 (no) | 1994-08-29 |
Family
ID=25334385
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO943198A NO943198D0 (no) | 1992-03-31 | 1994-08-29 | Antisensoligonukleotidinhibering av papillomavirus |
Country Status (11)
Country | Link |
---|---|
US (3) | US5457189A (no) |
EP (1) | EP0637316A4 (no) |
JP (2) | JP2609424B2 (no) |
KR (1) | KR0160185B1 (no) |
AU (1) | AU671630B2 (no) |
CA (1) | CA2132424C (no) |
FI (1) | FI944523A0 (no) |
HU (1) | HUT69934A (no) |
IL (1) | IL105241A0 (no) |
NO (1) | NO943198D0 (no) |
WO (1) | WO1993020095A1 (no) |
Families Citing this family (108)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6174870B1 (en) * | 1989-12-04 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of papillomavirus |
US5457189A (en) * | 1989-12-04 | 1995-10-10 | Isis Pharmaceuticals | Antisense oligonucleotide inhibition of papillomavirus |
US7119184B2 (en) | 1991-08-12 | 2006-10-10 | Isis Pharmaceuticals, Inc. | Oligonucleotides having A-DNA form and B-DNA form conformational geometry |
US6369209B1 (en) | 1999-05-03 | 2002-04-09 | Isis Pharmaceuticals, Inc. | Oligonucleotides having A-DNA form and B-DNA form conformational geometry |
US6727230B1 (en) | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
WO1995026204A1 (en) * | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
CN1043045C (zh) * | 1994-04-14 | 1999-04-21 | 同济医科大学 | 抑制内皮素生成的寡核苷酸及其应用 |
WO1995028942A1 (en) * | 1994-04-26 | 1995-11-02 | Genta Incorporated | Antisense oligomers for inhibiting human papillomaviruses |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US5858987A (en) * | 1995-05-05 | 1999-01-12 | Mitotix, Inc. | E6AP antisense constructs and methods of use |
AU5738996A (en) * | 1995-05-11 | 1996-11-29 | Genetic Therapy, Inc. | Gene therapy through transduction of oral epithelial cells |
US6458940B2 (en) * | 1995-06-06 | 2002-10-01 | Hybridon, Inc. | HPV-specific oligonucleotides |
US6509149B2 (en) * | 1995-06-06 | 2003-01-21 | Hybridon, Inc. | HPV-specific oligonucleotides |
US7566455B1 (en) | 1995-06-07 | 2009-07-28 | Gpc Biotech, Inc. | E6AP-binding proteins |
US6111085A (en) | 1996-09-13 | 2000-08-29 | Isis Pharmaceuticals, Inc. | Carbamate-derivatized nucleosides and oligonucleosides |
AU5333298A (en) | 1996-12-27 | 1998-07-31 | Instituto De Investigaciones Bioquimicas Fundacion Campomar | Compositions and methods for tumour therapy |
US6127533A (en) | 1997-02-14 | 2000-10-03 | Isis Pharmaceuticals, Inc. | 2'-O-aminooxy-modified oligonucleotides |
US6172209B1 (en) | 1997-02-14 | 2001-01-09 | Isis Pharmaceuticals Inc. | Aminooxy-modified oligonucleotides and methods for making same |
US6576752B1 (en) | 1997-02-14 | 2003-06-10 | Isis Pharmaceuticals, Inc. | Aminooxy functionalized oligomers |
US6084090A (en) * | 1997-09-05 | 2000-07-04 | The United States Of America As Represented By The Department Of Health And Human Services | Human papilloma virus anti-sense oligonucleotides |
AU2002300401C1 (en) * | 1997-09-05 | 2006-10-05 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Human papilloma virus anti-sense oligonucleotides |
AUPP249298A0 (en) * | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
NZ547283A (en) * | 1998-03-20 | 2008-06-30 | Commw Scient Ind Res Org | Control of gene expression |
US6306105B1 (en) * | 1998-05-14 | 2001-10-23 | Scimed Life Systems, Inc. | High performance coil wire |
US6841539B1 (en) | 1998-05-21 | 2005-01-11 | Isis Pharmaceuticals, Inc. | Compositions and methods for topical delivery of oligonucleotides |
SI1077722T1 (sl) | 1998-05-22 | 2007-02-28 | Ottawa Health Research Inst | Metode in produkti za induciranje sluznicne imunosti |
US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
US6867294B1 (en) | 1998-07-14 | 2005-03-15 | Isis Pharmaceuticals, Inc. | Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages |
US6242589B1 (en) | 1998-07-14 | 2001-06-05 | Isis Pharmaceuticals, Inc. | Phosphorothioate oligonucleotides having modified internucleoside linkages |
US6277967B1 (en) | 1998-07-14 | 2001-08-21 | Isis Pharmaceuticals, Inc. | Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages |
US6335194B1 (en) | 1998-09-29 | 2002-01-01 | Isis Pharmaceuticals, Inc. | Antisense modulation of survivin expression |
US6077709A (en) | 1998-09-29 | 2000-06-20 | Isis Pharmaceuticals Inc. | Antisense modulation of Survivin expression |
WO2000027795A1 (en) | 1998-11-12 | 2000-05-18 | Invitrogen Corporation | Transfection reagents |
US6492111B1 (en) * | 1998-11-25 | 2002-12-10 | Isis Pharmaceuticals, Inc. | In situ binary synthesis of biologically effective molecules |
ID30093A (id) | 1999-02-12 | 2001-11-01 | Sankyo Co | Analog-analog nukleosida dan oligonukleotida baru |
WO2000061804A1 (en) * | 1999-04-14 | 2000-10-19 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
JP4151751B2 (ja) * | 1999-07-22 | 2008-09-17 | 第一三共株式会社 | 新規ビシクロヌクレオシド類縁体 |
US6423885B1 (en) | 1999-08-13 | 2002-07-23 | Commonwealth Scientific And Industrial Research Organization (Csiro) | Methods for obtaining modified phenotypes in plant cells |
US6147200A (en) * | 1999-08-19 | 2000-11-14 | Isis Pharmaceuticals, Inc. | 2'-O-acetamido modified monomers and oligomers |
US6200746B1 (en) | 1999-08-25 | 2001-03-13 | Pharmacia & Upjohn Company | Methods of identifying anti-viral agents |
US6641994B2 (en) | 1999-08-25 | 2003-11-04 | Pharmacia & Upjohn Company | Methods of identifying anti-viral agents |
AU2001249622B2 (en) | 2000-03-30 | 2007-06-07 | Massachusetts Institute Of Technology | RNA sequence-specific mediators of RNA interference |
EP1315507A4 (en) * | 2000-04-11 | 2004-06-16 | Micrologix Biotech Inc | HPV-SPECIFIC SHORT OLIGOMERS |
WO2002034879A2 (en) * | 2000-10-27 | 2002-05-02 | Invitrogen Corporation | Method for introducing antisense oligonucleotides into eucaryotic cells |
WO2002044321A2 (en) * | 2000-12-01 | 2002-06-06 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Rna interference mediating small rna molecules |
DK1446162T3 (da) | 2001-08-17 | 2008-12-08 | Coley Pharm Gmbh | Kombinationsmotiv-immunstimulatoriske oligonukleotider med forbedret aktivitet |
DE10154831A1 (de) * | 2001-11-08 | 2003-06-05 | Deutsches Krebsforsch | PNA-Konjugat oder PNA-Konjugat-Gemisch zur Therapie von mit HPV in Zusammenhang stehenden Erkrankungen |
CA2491034A1 (en) * | 2002-06-26 | 2004-01-08 | The Penn State Research Foundation | Methods and materials for treating human papillomavirus infections |
US7998492B2 (en) | 2002-10-29 | 2011-08-16 | Coley Pharmaceutical Group, Inc. | Methods and products related to treatment and prevention of hepatitis C virus infection |
JP2006512927A (ja) | 2002-12-11 | 2006-04-20 | コーリー ファーマシューティカル グループ,インコーポレイテッド | 5’cpg核酸およびその使用方法 |
US20050123902A1 (en) * | 2003-05-21 | 2005-06-09 | President And Fellows Of Harvard College | Human papillomavirus inhibitors |
WO2005030041A2 (en) | 2003-09-25 | 2005-04-07 | Third Wave Technologies, Inc. | Detection of hpv |
US8251110B2 (en) * | 2004-08-17 | 2012-08-28 | Mbhd, Llc | Filling adapter |
WO2006104381A1 (en) * | 2005-03-30 | 2006-10-05 | Labo Bio-Medical Investments | Identification of beta-papillomavirus dna by type-specific reverse hybridization |
WO2007038241A2 (en) * | 2005-09-22 | 2007-04-05 | Maine Medical Center Research | Modulation of mesenchymal and metastatic cell growth |
US8288354B2 (en) | 2005-12-28 | 2012-10-16 | The Scripps Research Institute | Natural antisense and non-coding RNA transcripts as drug targets |
US8080643B2 (en) * | 2006-09-05 | 2011-12-20 | Third Wave Technologies, Inc. | HPV primers |
EP2352830B1 (en) | 2008-10-03 | 2019-01-16 | CuRNA, Inc. | Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1 |
MX2011005912A (es) | 2008-12-04 | 2011-06-17 | Opko Curna Llc | Tratamiento de enfermedades relacionadas con factor de crecimiento endotelial vascular por inhibicion de transcrito antisentido natural para factor de crecimiento endotelial vascular. |
KR20110091796A (ko) | 2008-12-04 | 2011-08-12 | 오피케이오 큐알엔에이, 엘엘씨 | 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료 |
EP2370579B1 (en) | 2008-12-04 | 2017-03-29 | CuRNA, Inc. | Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo |
KR101682735B1 (ko) | 2009-02-12 | 2016-12-06 | 큐알엔에이, 인크. | 뇌 유래된 신경영양성 인자 (bdnf)에 대한 자연 안티센스 전사체의 저해에 의한 뇌 유래된 신경영양성 인자 (bdnf) 관련된 질환의 치료 |
CN102482677B (zh) | 2009-03-16 | 2017-10-17 | 库尔纳公司 | 通过抑制nrf2的天然反义转录物治疗核因子(红细胞衍生2)‑样2(nrf2)相关疾病 |
JP5904935B2 (ja) | 2009-03-17 | 2016-04-20 | クルナ・インコーポレーテッド | デルタ様1ホモログ(dlk1)に対する天然アンチセンス転写物の抑制によるdlk1関連疾患の治療 |
CA2761142C (en) | 2009-05-06 | 2021-06-08 | Opko Curna, Llc | Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp |
CA2761152A1 (en) | 2009-05-06 | 2010-11-11 | Opko Curna, Llc | Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene |
ES2618572T3 (es) | 2009-05-08 | 2017-06-21 | Curna, Inc. | Tratamiento de enfermedades relacionadas con la familia de la distrofina mediante inhibición de un transcrito antisentido natural para la familia de dmd |
KR101749356B1 (ko) | 2009-05-18 | 2017-07-06 | 큐알엔에이, 인크. | 재편성 인자에 대한 천연 안티센스 전사체의 억제에 의한 재편성 인자 관련된 질환의 치료 |
KR101703695B1 (ko) | 2009-05-22 | 2017-02-08 | 큐알엔에이, 인크. | 전사 인자 e3(tfe3)에 대한 천연 안티센스 전사체의 억제에 의해 tfe3 및 인슐린 수용체 기질 2(irs2)의 치료 |
EP2435571B1 (en) | 2009-05-28 | 2016-12-14 | CuRNA, Inc. | Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene |
KR101702689B1 (ko) | 2009-06-16 | 2017-02-06 | 큐알엔에이, 인크. | Pon1에 대한 천연 안티센스 전사체의 억제에 의한 파라옥소나제 1(pon1) 관련된 질환의 치료 |
KR101801404B1 (ko) | 2009-06-16 | 2017-12-20 | 큐알엔에이, 인크. | 콜라겐 유전자에 대한 천연 안티센스 전사체의 억제에 의한 콜라겐 유전자 관련된 질환의 치료 |
ES2618894T3 (es) | 2009-06-24 | 2017-06-22 | Curna, Inc. | Tratamiento de enfermedades relacionadas con el receptor del factor de necrosis tumoral 2 (tnfr2) por inhibición del transcrito natural antisentido para tnfr2 |
CN102482672B (zh) | 2009-06-26 | 2016-11-09 | 库尔纳公司 | 通过抑制唐氏综合征基因的天然反义转录物治疗唐氏综合征基因相关疾病 |
JP2013500017A (ja) | 2009-07-24 | 2013-01-07 | カッパーアールエヌエー,インコーポレイテッド | サ−チュイン(sirt)への天然アンチセンス転写物の阻止によるサ−チュイン(sirt)関連疾患の治療 |
CN102762731B (zh) | 2009-08-05 | 2018-06-22 | 库尔纳公司 | 通过抑制针对胰岛素基因(ins)的天然反义转录物来治疗胰岛素基因(ins)相关的疾病 |
JP6189594B2 (ja) | 2009-08-11 | 2017-08-30 | クルナ・インコーポレーテッド | アディポネクチン(adipoq)に対する天然アンチセンス転写物の抑制によるアディポネクチン(adipoq)関連疾患の治療 |
EP2982755B1 (en) | 2009-08-21 | 2020-10-07 | CuRNA, Inc. | Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip |
EP2470657B1 (en) | 2009-08-25 | 2019-10-23 | CuRNA, Inc. | Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap |
NO2480669T3 (no) | 2009-09-25 | 2018-04-07 | ||
RU2639550C2 (ru) | 2009-12-16 | 2017-12-21 | Курна, Инк. | Лечение заболеваний, связанных с сайт-1 мембраносвязанной пептидазой транскрипционных факторов (mbtps1), путем ингибирования природного антисмыслового транскрипта к mbtps1 |
EP2515947B1 (en) | 2009-12-23 | 2021-10-06 | CuRNA, Inc. | Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2 |
RU2609631C2 (ru) | 2009-12-23 | 2017-02-02 | Курна, Инк. | Лечение заболеваний, связанных с фактором роста гепатоцитов (фрг), посредством ингибирования природного антисмыслового транскрипта к фрг |
KR101838305B1 (ko) | 2009-12-29 | 2018-03-13 | 큐알엔에이, 인크. | NRF1(Nuclear Respiratory Factor 1)에 대한 천연 안티센스 전사체의 억제에 의한 핵 호흡 인자 1 관련된 질환의 치료 |
CN102770540B (zh) | 2009-12-29 | 2017-06-23 | 库尔纳公司 | 通过抑制肿瘤蛋白63(p63)的天然反义转录物而治疗p63相关疾病 |
US20120289583A1 (en) | 2009-12-31 | 2012-11-15 | Curna, Inc. | Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3) |
CN102906264B (zh) | 2010-01-04 | 2017-08-04 | 库尔纳公司 | 通过抑制干扰素调节因子8(irf8)的天然反义转录物而治疗irf8相关疾病 |
WO2011085066A2 (en) | 2010-01-06 | 2011-07-14 | Curna, Inc. | Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene |
US9200277B2 (en) | 2010-01-11 | 2015-12-01 | Curna, Inc. | Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG |
ES2671877T3 (es) | 2010-01-25 | 2018-06-11 | Curna, Inc. | Tratamiento de enfermedades relacionadas con la RNASA (H1) mediante inhibición del transcrito antisentido natural a RNASA H1 |
KR101838308B1 (ko) | 2010-02-22 | 2018-03-13 | 큐알엔에이, 인크. | 피롤린-5-카르복실레이트 환원효소 1(pycr1)에 대한 천연 안티센스 전사체의 억제에 의한 pycr1과 관련된 질환의 치료 |
RU2612884C2 (ru) | 2010-04-02 | 2017-03-13 | Курна, Инк. | Лечение заболеваний, связанных с колониестимулирующим фактором 3 (csf3), путем ингибирования природного антисмыслового транскрипта k csf3 |
KR101900962B1 (ko) | 2010-04-09 | 2018-09-20 | 큐알엔에이, 인크. | 섬유아세포 성장 인자 21 (fgf21)에 대한 자연 안티센스 전사체의 저해에 의한 섬유아세포 성장 인자 21 (fgf21) 관련된 질환의 치료 |
US9089588B2 (en) | 2010-05-03 | 2015-07-28 | Curna, Inc. | Treatment of sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a sirtuin (SIRT) |
TWI531370B (zh) | 2010-05-14 | 2016-05-01 | 可娜公司 | 藉由抑制par4天然反股轉錄本治療par4相關疾病 |
DK2576783T3 (en) | 2010-05-26 | 2018-03-12 | Curna Inc | TREATMENT OF ATONAL HOMOLOGY 1- (ATOH1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS AT ATOH1 |
RU2620978C2 (ru) | 2010-05-26 | 2017-05-30 | Курна, Инк. | Лечение заболеваний, связанных с метионинсульфоксидредуктазой а (msra), путем ингибирования природного антисмыслового транскрипта гена msra |
PL2585596T3 (pl) | 2010-06-23 | 2021-06-28 | Curna, Inc. | Leczenie chorób związanych z podjednostką alfa kanału sodowego bramkowanego napięciem (SCNA) poprzez hamowanie naturalnego transkryptu antysensownego SCNA |
EP2593547B1 (en) | 2010-07-14 | 2017-11-15 | CuRNA, Inc. | Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg |
US8993533B2 (en) | 2010-10-06 | 2015-03-31 | Curna, Inc. | Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4 |
CA2815212A1 (en) | 2010-10-22 | 2012-04-26 | Curna, Inc. | Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua |
WO2012068340A2 (en) | 2010-11-18 | 2012-05-24 | Opko Curna Llc | Antagonat compositions and methods of use |
KR102010598B1 (ko) | 2010-11-23 | 2019-08-13 | 큐알엔에이, 인크. | Nanog에 대한 자연 안티센스 전사체의 저해에 의한 nanog 관련된 질환의 치료 |
JP6188686B2 (ja) | 2011-06-09 | 2017-08-30 | カッパーアールエヌエー,インコーポレイテッド | フラタキシン(fxn)への天然アンチセンス転写物の阻害によるfxn関連疾患の治療 |
EA029151B1 (ru) | 2011-09-06 | 2018-02-28 | Курна, Инк. | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АЛЬФА-СУБЪЕДИНИЦАМИ ПОТЕНЦИАЛЗАВИСИМЫХ НАТРИЕВЫХ КАНАЛОВ (SCNxA), С ПОМОЩЬЮ МАЛЫХ МОЛЕКУЛ |
WO2016011203A1 (en) | 2014-07-15 | 2016-01-21 | Life Technologies Corporation | Compositions with lipid aggregates and methods for efficient delivery of molecules to cells |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3625257A1 (de) * | 1986-07-23 | 1988-02-04 | Behringwerke Ag | Expressionsprodukte der menschlichen papillomviren typ 16 und 18, fuer diese proteine spezifische antikoerper und diese antikoerper bzw. entsprechende dna enthaltende diagnostika |
CA1339729C (en) * | 1988-10-26 | 1998-03-17 | Wayne D. Lancaster | Human papillomavirus type 52 dna sequences and methods for employing thesame |
US5457189A (en) * | 1989-12-04 | 1995-10-10 | Isis Pharmaceuticals | Antisense oligonucleotide inhibition of papillomavirus |
CA2070664C (en) * | 1989-12-04 | 2000-08-08 | Christopher K. Mirabelli | Antisense oligonucleotide inhibition of papillomavirus |
CA2121144C (en) * | 1991-10-15 | 2001-07-31 | Phillip Dan Cook | Oligonucleotides having chiral phosphorus linkages |
EP1331011A3 (en) * | 1991-10-24 | 2003-12-17 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
-
1992
- 1992-03-31 US US07/860,925 patent/US5457189A/en not_active Expired - Lifetime
-
1993
- 1993-03-31 JP JP5517699A patent/JP2609424B2/ja not_active Expired - Fee Related
- 1993-03-31 IL IL105241A patent/IL105241A0/xx unknown
- 1993-03-31 HU HU9402822A patent/HUT69934A/hu unknown
- 1993-03-31 WO PCT/US1993/003075 patent/WO1993020095A1/en not_active Application Discontinuation
- 1993-03-31 KR KR1019940703131A patent/KR0160185B1/ko not_active IP Right Cessation
- 1993-03-31 US US08/307,682 patent/US5665580A/en not_active Expired - Fee Related
- 1993-03-31 EP EP93908714A patent/EP0637316A4/en not_active Ceased
- 1993-03-31 AU AU39438/93A patent/AU671630B2/en not_active Ceased
- 1993-03-31 CA CA002132424A patent/CA2132424C/en not_active Expired - Fee Related
-
1994
- 1994-08-29 NO NO943198A patent/NO943198D0/no unknown
- 1994-09-29 FI FI944523A patent/FI944523A0/fi not_active Application Discontinuation
- 1994-11-04 US US08/334,215 patent/US5681944A/en not_active Expired - Fee Related
-
1996
- 1996-08-14 JP JP8214477A patent/JP2737894B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
KR0160185B1 (ko) | 1998-11-16 |
IL105241A0 (en) | 1993-07-08 |
US5681944A (en) | 1997-10-28 |
EP0637316A4 (en) | 1997-07-16 |
CA2132424C (en) | 2000-03-14 |
US5665580A (en) | 1997-09-09 |
CA2132424A1 (en) | 1993-10-14 |
JP2737894B2 (ja) | 1998-04-08 |
KR950700317A (ko) | 1995-01-16 |
US5457189A (en) | 1995-10-10 |
HU9402822D0 (en) | 1995-01-30 |
JP2609424B2 (ja) | 1997-05-14 |
AU671630B2 (en) | 1996-09-05 |
HUT69934A (en) | 1995-09-28 |
EP0637316A1 (en) | 1995-02-08 |
AU3943893A (en) | 1993-11-08 |
FI944523A (fi) | 1994-09-29 |
FI944523A0 (fi) | 1994-09-29 |
JPH07501709A (ja) | 1995-02-23 |
WO1993020095A1 (en) | 1993-10-14 |
JPH09117291A (ja) | 1997-05-06 |
NO943198D0 (no) | 1994-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO943198L (no) | Antisensoligonukleotidinhibering av papillomavirus | |
FI922593A (fi) | Inhibition av papillomavirus med çantisenseç-oligonukleotider. | |
DE60024660D1 (de) | Menschliche rnase h und entsprechende oligonukleotidverbindungen | |
DE69433626D1 (de) | N-2 substituierte purine | |
ATE154029T1 (de) | 7-deazapurin modifizierte oligonukleotide | |
HU9300398D0 (en) | Oligo-nucleotides influencing effect of infection by cyto-megalo virus | |
ES2108748T3 (es) | Amplificacion de acidos nucleicos con actividad de rna polimerasa dependiente de dna, de rna replicasas. | |
DE69133511D1 (de) | Zuckermodifizierte oligonukleotide zum erkennen und steuern der genexpression | |
DK0677056T3 (da) | Oligonukleotid-alkylphosphonater og -alkylphosphonothioater | |
WO2005014806A3 (en) | Conserved hbv and hcv sequences useful for gene silencing | |
BR9904449A (pt) | Processo para o preparo de ácido pantotênico através de amplificação de sequências de nucleotìdeos, as quais codificam a redutase de cetopantoato | |
Bailly et al. | The influence of the 2‐amino group of guanine on DNA conformation. Uranyl and DNase I probing of inosine/diaminopurine substituted DNA. | |
Park et al. | Inhibition of HSV-1 replication and reactivation by the mutation-insensitive transcription inhibitor tetra-O-glycyl-nordihydroguaiaretic acid | |
NO965017D0 (no) | Oligonukleotider med anti-cytomegalovirus aktivitet | |
NO922169L (no) | Antisensoligonukleotidinhibisjon av papillomavirus | |
ES2048652A1 (es) | Procedimientos de amplificacion de genoma para la deteccion e identificacion de secuencias genomicas relacionadas. | |
MD2149G2 (ro) | Primer oligonucleotidic pentru depistarea ARN-ului virusului hepatitei C | |
GB2300259B (en) | Diagnostic and therapeutic system | |
DE10393716D2 (de) | Decoy-Oligonukleotid-Hemmung der CD40-Expression | |
WO2002068582A3 (en) | Phosphorothioate (p=s) oligonucleotides containing modified nucleotides with six-membered azasugars and use for aids therapy thereof | |
HUP0400987A2 (hu) | Vírusellenes szerek |